Schroder Investment Management Group’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-2,472
| Closed | -$453K | – | 1210 |
|
|
2024
Q4 | $453K | Hold |
2,472
| – | – | ﹤0.01% | 1112 |
|
|
2024
Q3 | $490K | Sell |
2,472
-22
| -0.9% | -$4.57K | ﹤0.01% | 1107 |
|
|
2024
Q2 | $515K | Hold |
2,494
| – | – | ﹤0.01% | 1100 |
|
|
2024
Q1 | $676K | Buy |
2,494
+49
| +2% | +$11.7K | ﹤0.01% | 1076 |
|
|
2023
Q4 | $578K | Hold |
2,445
| – | – | ﹤0.01% | 1072 |
|
|
2023
Q3 | $479K | Sell |
2,445
-59
| -2% | -$12.1K | ﹤0.01% | 1101 |
|
|
2023
Q2 | $526K | Sell |
2,504
-201
| -7% | -$40K | ﹤0.01% | 1117 |
|
|
2023
Q1 | $546K | Buy |
2,705
+304
| +13% | +$68.9K | ﹤0.01% | 1130 |
|
|
2022
Q4 | $523K | Hold |
2,401
| – | – | ﹤0.01% | 1138 |
|
|
2022
Q3 | $473K | Buy |
2,401
+147
| +7% | +$31.7K | ﹤0.01% | 1153 |
|
|
2022
Q2 | $495K | Buy |
2,254
+862
| +62% | +$211K | ﹤0.01% | 1173 |
|
|
2022
Q1 | $403K | Buy |
1,392
+774
| +125% | +$239K | ﹤0.01% | 1243 |
|
|
2021
Q4 | $233K | Sell |
618
-15,004
| -96% | -$5.83M | ﹤0.01% | 1215 |
|
|
2021
Q3 | $6.45M | Buy |
15,622
+15,004
| +2,428% | +$6.23M | 0.01% | 727 |
|
|
2021
Q2 | $229K | Sell |
618
-19,258
| -97% | -$6.43M | ﹤0.01% | 1315 |
|
|
2021
Q1 | $5.76M | Sell |
19,876
-2,575
| -11% | -$716K | 0.01% | 790 |
|
|
2020
Q4 | $5.61M | Sell |
22,451
-388
| -2% | -$92.4K | 0.01% | 780 |
|
|
2020
Q3 | $5.23M | Sell |
22,839
-3,070
| -12% | -$637K | 0.01% | 718 |
|
|
2020
Q2 | $4.52M | Sell |
25,909
-5,130
| -17% | -$819K | 0.01% | 691 |
|
|
2020
Q1 | $4.12M | Sell |
31,039
-743
| -2% | -$111K | 0.01% | 696 |
|
|
2019
Q4 | $4.86M | Buy |
31,782
+1,399
| +5% | +$194K | 0.01% | 759 |
|
|
2019
Q3 | $4.03M | Sell |
30,383
-118,135
| -80% | -$15.8M | 0.01% | 784 |
|
|
2019
Q2 | $21.1M | Buy |
148,518
+34,201
| +30% | +$4.64M | 0.01% | 592 |
|
|
2019
Q1 | $16.6M | Sell |
114,317
-17,654
| -13% | -$2.32M | 0.03% | 496 |
|
|
2018
Q4 | $14.9M | Buy |
131,971
+11,531
| +10% | +$1.44M | 0.03% | 497 |
|
|
2018
Q3 | $16.2M | Buy |
120,440
+42,978
| +55% | +$5.3M | 0.03% | 509 |
|
|
2018
Q2 | $8.62M | Buy |
77,462
+29,332
| +61% | +$3.17M | 0.02% | 628 |
|
|
2018
Q1 | $5.14M | Sell |
48,130
-13,152
| -21% | -$1.42M | 0.01% | 724 |
|
|
2017
Q4 | $6.71M | Buy |
61,282
+38,995
| +175% | +$4.24M | 0.01% | 728 |
|
|
2017
Q3 | $2.38M | Buy |
22,287
+6,138
| +38% | +$631K | ﹤0.01% | 863 |
|
|
2017
Q2 | $1.64M | Sell |
16,149
-979
| -6% | -$90.1K | ﹤0.01% | 900 |
|
|
2017
Q1 | $1.53M | Buy |
17,128
+3,804
| +29% | +$323K | ﹤0.01% | 891 |
|
|
2016
Q4 | $1.01M | Sell |
13,324
-508
| -4% | -$38.6K | ﹤0.01% | 916 |
|
|
2016
Q3 | $1.15M | Sell |
13,832
-23,935
| -63% | -$2.01M | ﹤0.01% | 905 |
|
|
2016
Q2 | $3.11M | Buy |
37,767
+20,521
| +119% | +$1.69M | 0.01% | 782 |
|
|
2016
Q1 | $1.3M | Buy |
+17,246
| New | +$1.28M | ﹤0.01% | 884 |
|
|
2015
Q3 | – | Sell |
-46,600
| Closed | -$3.28M | – | 1183 |
|
|
2015
Q2 | $3.28M | Hold |
46,600
| – | – | 0.01% | 784 |
|
|
2015
Q1 | $3.71M | Sell |
46,600
-5,200
| -10% | -$384K | 0.01% | 795 |
|
|
2014
Q4 | $3.3M | Hold |
51,800
| – | – | 0.01% | 834 |
|
|
2014
Q3 | $3.09M | Sell |
51,800
-10,900
| -17% | -$624K | ﹤0.01% | 856 |
|
|
2014
Q2 | $3.36M | Hold |
62,700
| – | – | ﹤0.01% | 818 |
|
|
2014
Q1 | $3.78M | Buy |
+62,700
| New | +$3.65M | ﹤0.01% | 827 |
|
Other funds holding CRL
IC
Schroder Investment Management Group's CRL Position: Q1 2025 in Review
Schroder Investment Management Group sold out of Charles River Laboratories (CRL) in Q1 2025, closing a stake of 2,472 shares — an estimated $453K sold.
Schroder Investment Management Group first reported a position in CRL in Q1 2014 and held it in 42 quarters. The position peaked at $21.1M in Q2 2019. 561 funds tracked by Wall St. Rank hold CRL as of Q1 2025.
- Schroder Investment Management Group reported no remaining Charles River Laboratories position as of Q1 2025 after selling out during the quarter.
- Schroder Investment Management Group sold 2,472 Charles River Laboratories shares in Q1 2025, an estimated $453K.
- Schroder Investment Management Group first reported a position in Charles River Laboratories in Q1 2014 and held it in 42 quarters.
- Schroder Investment Management Group's Charles River Laboratories position peaked at $21.1M in Q2 2019.
- 561 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2025.
Based on Schroder Investment Management Group's 13F filing for Q1 2025, filed 13 May 2025.